StockNews.com Upgrades Pulse Biosciences (NASDAQ:PLSE) to Sell

Pulse Biosciences (NASDAQ:PLSE) was upgraded by stock analysts at StockNews.com to a “sell” rating in a report released on Thursday.

Pulse Biosciences Stock Up 3.0 %

Shares of PLSE opened at $17.65 on Thursday. The stock has a 50-day moving average of $17.68 and a two-hundred day moving average of $16.40. Pulse Biosciences has a one year low of $6.59 and a one year high of $22.69.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.21) EPS for the quarter. During the same period in the prior year, the business earned ($0.19) earnings per share.

Insider Activity

In related news, Director Robert W. Duggan acquired 56,054 shares of the firm’s stock in a transaction dated Wednesday, December 11th. The stock was acquired at an average price of $17.35 per share, with a total value of $972,536.90. Following the acquisition, the director now directly owns 42,228,057 shares in the company, valued at $732,656,788.95. This represents a 0.13 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 71.50% of the company’s stock.

Hedge Funds Weigh In On Pulse Biosciences

Several institutional investors and hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of Pulse Biosciences by 28.8% in the 1st quarter. Vanguard Group Inc. now owns 847,212 shares of the company’s stock valued at $7,379,000 after buying an additional 189,227 shares during the period. State Street Corp raised its holdings in Pulse Biosciences by 17.8% in the 3rd quarter. State Street Corp now owns 461,333 shares of the company’s stock worth $8,092,000 after purchasing an additional 69,696 shares during the period. Geode Capital Management LLC raised its holdings in Pulse Biosciences by 7.8% in the 3rd quarter. Geode Capital Management LLC now owns 457,165 shares of the company’s stock worth $8,020,000 after purchasing an additional 33,200 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Pulse Biosciences by 193.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 148,114 shares of the company’s stock worth $2,598,000 after purchasing an additional 97,565 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Pulse Biosciences by 23.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 50,914 shares of the company’s stock worth $570,000 after purchasing an additional 9,639 shares during the period. Institutional investors and hedge funds own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.